Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase-I Study in Healthy Male Subjects to Investigate Safety, Tolerability and Pharmacokinetics of Orally Inhaled Multiple Doses of SB010, a Human GATA-3-specific DNAzyme Solution for Nebulisation

X
Trial Profile

Phase-I Study in Healthy Male Subjects to Investigate Safety, Tolerability and Pharmacokinetics of Orally Inhaled Multiple Doses of SB010, a Human GATA-3-specific DNAzyme Solution for Nebulisation

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anti-GATA3 gene-therapy (Primary)
  • Indications Asthma
  • Focus Adverse reactions
  • Sponsors sterna biologicals
  • Most Recent Events

    • 17 May 2015 According to Sterna Biologics media release, results of this other two Phase I trials (see profile 216392 and 209662) were published in the 2015 Journal of Allergy and Clinical Immunology.
    • 11 Sep 2013 Results presented at the 23rd Annual Congress of the European Respiratory Society.
    • 10 Apr 2012 Actual initiation date Apr 2012 added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top